Olivier Tredan, MD, PhD, on Advanced Refractory Cancer and Molecular Screening
2017 ASCO Annual Meeting
Olivier Tredan, MD, PhD, of the Centre Léon Bérard, discusses results from ProfilER, a study that explored the use of cancer cell genomic alterations to guide treatment in patients with advanced refractory cancer. (Abstract LBA100)
Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.
Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity measured across 3 decades. (LBA10500)